Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

APC 8015

A vaccine used to treat prostate cancer that has spread to other parts of the body. It is used in patients who have few or no symptoms and whose cancer is castration resistant (has not responded to treatments that lower testosterone levels). APC 8015 is made from a patient’s immune cells that have been treated in the laboratory with GM-CSF (a type of growth factor) and a protein found on prostate cancer cells. APC 8015 may help the immune system kill prostate cancer cells. It is a type of autologous cellular immunotherapy and a type of dendritic cell vaccine. Also called Provenge and sipuleucel-T.
More Information
Search NCI's Dictionary of Cancer Terms